Podcast: Selecting a CDMO? Know your molecule, know your timeline

Dan Stanton, Managing editor

September 12, 2022

With expertise in development and CMC in short supply globally, CDMO choice is absolutely critical for sponsors relying on them to accelerate development pathway, says Pharmatech Associates.

Ahead of November’s CPhI Worldwide event in Frankfurt, Germany, BioProcess Insider hosted a LinkedIn Live discussion with Bikash Chatterjee and Stephanie Gaulding, the respective CEO and MD at drug development consultancy firm Pharmatech Associates about current outsourcing strategies and how to go about selecting a CDMO partner.

Listen to the full discussion, as part of the BioProcess Insider Expression Platform, below, or at Spotify, Apple, or wherever you get your podcasts.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like